Our evaluation of APEX1 expression and clinicopathological data revealed a correlation between cytoplasmic APEX1 expression in tumor cells and shorter DFS times in patients with HCC or intrahepatic CC. This evidence concerns the gene APEX1 and cholangiocarcinoma.